--- title: "ACCESS GPO 宣佈了一項優選戰略商業協議，將向門診手術中心提供 Affera™映射和消融系統及 Sphere-9™導管" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/279061308.md" description: "ACCESS GPO 宣佈與美敦力達成多年協議，向美國的門診手術中心（ASC）提供 Affera™ 映射和消融系統及 Sphere-9™ 導管。此次合作旨在增強對先進技術的獲取，以治療心臟心律失常，特別是通過脈衝場消融（PFA）。Sphere-9 導管因其安全性、有效性和高效性而受到認可，適用於各種心律失常。該協議強調了在 ASC 中由醫生主導的治理的重要性，以確保優質護理和成功的技術採用" datetime: "2026-03-13T14:35:44.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/279061308.md) - [en](https://longbridge.com/en/news/279061308.md) - [zh-HK](https://longbridge.com/zh-HK/news/279061308.md) --- # ACCESS GPO 宣佈了一項優選戰略商業協議，將向門診手術中心提供 Affera™映射和消融系統及 Sphere-9™導管 **ACCESS GPO Announces Preferred Strategic Commercial Agreement to Provide Affera™ Mapping and Ablation System with Sphere-9™ Catheter to Ambulatory Surgery Centers** **Agreement will expand access to next-generation technology for cardiac electrophysiology procedures** ACCESS GPO today announced a preferred, multi-year agreement with Medtronic to support availability of the Affera™ Mapping and Ablation System with Sphere-9™ Catheter in ambulatory surgery centers (ASCs) across the United States. The agreement is designed to help physician-led ASCs gain earlier access to next-generation technology for treatment of cardiac arrhythmias in the ASC setting. Pulsed field ablation (PFA) is emerging as one of the most important advances in the treatment of atrial fibrillation. In the ASC setting, successful adoption depends not only on the promise of the technology itself, but on whether it can be implemented with the right workflow alignment, efficiency and strategic support. ACCESS GPO is partnering with Medtronic to help ASCs meet that challenge. As a physician-led group purchasing organization focused on electrophysiology in ASCs, ACCESS GPO chose the Affera system and Sphere-9 catheter for its safety, efficacy and versatility for patients. Sphere-9 is an all-in-one, high density mapping and dual energy (radiofrequency and pulsed field) ablation catheter that is being rapidly adopted by electrophysiologists in the U.S. and around the world. In addition to its highly favorable safety and efficacy profile, Sphere-9 provides improved lab efficiency and workflow for physicians to address a variety of different arrhythmias, making it an excellent choice for the ASC environment. “This agreement is about broadening the reach of a new and safer treatment and ensuring independent, physician-led ASCs have a real opportunity to participate in the future of ablation,” said Dr. Vivek Reddy, Director of Cardiac Arrhythmia Services at The Mount Sinai Fuster Heart Hospital and the Mount Sinai Health System in New York City_._ “As innovation accelerates, physician-led centers should not have to wait for access, nor should the patients they treat.” “Physician governance of partnerships in ASCs is essential to ensure the focus remains on critical success factors such as clinical quality and sustainable adoption while also providing the best treatment for patients,” said Dr. Arash Aryana, Medical Director of Cardiovascular Services and the Cardiac Electrophysiology Laboratory at Mercy General Hospital in Sacramento, California. “Our goal is to support and foster strong physician governance as ASCs expand and evolve.” “With the rise of PFA, this is an exciting time in electrophysiology with safer and more efficient technologies available,” said Dr. Vijay Swarup, Executive Medical Director of Cardiac Electrophysiology at Arizona Heart Rhythm Center in Phoenix, Arizona “With ACCESS GPO, we are enabling physician-led ASCs to gain access to this innovation sooner, with the support needed for successful adoption.” **About ACCESS GPO** ACCESS GPO is a physician-led group purchasing organization focused on supporting ambulatory surgery centers, with a particular emphasis on cardiac electrophysiology. The organization works to improve access to advanced technologies, strengthen procedural economics, and preserve physician-led governance as more complex cardiovascular care moves into the outpatient setting. By building strategic vendor relationships around those principles, ACCESS GPO aims to strengthen the long-term foundation for advanced cardiac electrophysiology in ASCs. The organization believes that physician-led outpatient centers should be able to deliver high-level electrophysiology care without giving up control over governance, economics, or clinical standards. Media Contact: Jasmine Kaur, MBBS, MPH Media Relations ACCESS GPO jkaur@accesspartner.org View source version on businesswire.com: https://www.businesswire.com/news/home/20260312854786/en/ ### 相關股票 - [XBI.US](https://longbridge.com/zh-HK/quote/XBI.US.md) - [IHI.US](https://longbridge.com/zh-HK/quote/IHI.US.md) - [BIB.US](https://longbridge.com/zh-HK/quote/BIB.US.md) - [MDT.US](https://longbridge.com/zh-HK/quote/MDT.US.md) - [LABU.US](https://longbridge.com/zh-HK/quote/LABU.US.md) - [XHE.US](https://longbridge.com/zh-HK/quote/XHE.US.md) - [PBE.US](https://longbridge.com/zh-HK/quote/PBE.US.md) - [SBIO.US](https://longbridge.com/zh-HK/quote/SBIO.US.md) - [FBT.US](https://longbridge.com/zh-HK/quote/FBT.US.md) - [IBB.US](https://longbridge.com/zh-HK/quote/IBB.US.md) - [BBH.US](https://longbridge.com/zh-HK/quote/BBH.US.md) ## 相關資訊與研究 - [鉅亨速報 - Factset 最新調查：美敦力公司 (MDT-US) EPS 預估下修至 5.52 元，預估目標價為 111.00 元](https://longbridge.com/zh-HK/news/282861471.md) - [巨生醫細胞治療產品獲 SelectUSA Tech 醫療領域前 8 強 有助美國市場佈局](https://longbridge.com/zh-HK/news/282988767.md) - [藥廠 AI 合作潮！諾和諾德攜手 OpenAI 股價走揚](https://longbridge.com/zh-HK/news/282755292.md) - [鉅亨速報 - Factset 最新調查：阿里拉姆製藥 (ALNY-US) EPS 預估下修至 6.57 元，預估目標價為 447.00 元](https://longbridge.com/zh-HK/news/282708759.md) - [巨生醫細胞治療產品 MPB-2354 獲選 SelectUSA Tech 醫療領域前八強](https://longbridge.com/zh-HK/news/282972944.md)